Aimwell Partners Secures Agreement in Principle to Acquire $10 Million Intellectual Property Portfolio

Aimwell Partners Inc. (OTCID:AIMN), headquartered in Miami, Florida, revealed on August 6, 2026, that it has reached an agreement in principle to acquire a portfolio of intellectual property valued at around $10 million. This portfolio acquisition is designed to strengthen the long-term strategic position of AimwellBio, the company’s healthcare intelligence platform.

The proposed transaction remains contingent upon the completion of due diligence, negotiation and execution of definitive agreements, approval by all involved parties, and legal counsel reviews. Consequently, there is no guarantee that the acquisition will be finalized on the current terms or at all.

John Morgan, Chief Executive Officer of Aimwell Partners Inc., emphasized the significance of this milestone, stating, "Reaching an agreement in principle is an important milestone. While there is still meaningful work to be completed through due diligence and legal review, we believe this proposed acquisition has the potential to significantly enhance the value and capabilities of the AimwellBio platform. We look forward to sharing additional details after the transaction has closed."

To maintain the integrity of the ongoing process, Aimwell Partners has elected not to disclose the specific nature of the intellectual property or further transaction details until the acquisition is completed. After closing, the company intends to provide investors with comprehensive information about the acquired assets, their strategic importance, and how they will be integrated into AimwellBio’s platform.

Aimwell Partners Inc. is the parent company of AimwellBio, a healthcare intelligence platform focused on combining verified information with qualified professional expertise. The platform leverages a growing network of physicians, scientists, researchers, and industry professionals to develop infrastructure aimed at improving confidence, transparency, and decision-making across healthcare, life sciences, regulatory affairs, and investment research.

The company has committed to providing updates as appropriate and in compliance with applicable disclosure requirements.

This announcement contains forward-looking statements within the meaning of applicable securities laws. These statements include expectations regarding the proposed acquisition, asset valuation, strategic benefits, due diligence, execution of agreements, and future business plans. Such statements involve risks and uncertainties that could cause actual outcomes to differ materially, including the possibility that the transaction may not be completed, delays, regulatory or contractual challenges, market conditions, financing issues, and other factors beyond the company’s control. Readers are cautioned not to place undue reliance on these forward-looking statements, which are current as of the date of this release.

For further information, contact John Morgan, Chief Executive Officer, Aimwell Partners Inc., via email at corporate@aimwellbio.com.